BioAtla (BCAB) Common Equity (2020 - 2026)

BioAtla's Common Equity history runs 7 years deep, the most recent figure standing at -$37.3 million for Q1 2026.

• On a quarterly basis, Common Equity fell 6920.66% year-over-year to -$37.3 million in Q1 2026; TTM through Mar 2026 was -$37.3 million, a 6920.66% decrease from a year earlier, with the FY2025 full-year figure at -$36.2 million, down 353.69% from the prior year.
• Common Equity eased to -$37.3 million in Q1 2026 per BCAB's latest filing, from -$36.2 million in the prior quarter.
• Across five years, Common Equity topped out at $190.1 million in Q1 2022 and bottomed at -$37.3 million in Q1 2026.
• The 5-year median for Common Equity is $49.7 million (2024), against an average of $66.0 million.
• Across the five-year window, Common Equity fell 2.99% in 2022 and sank 6920.66% in 2026, its largest moves.
• Year by year, Common Equity stood at $180.3 million in 2022, then plunged by 60.81% to $70.7 million in 2023, then slumped by 79.82% to $14.3 million in 2024, then tumbled by 353.69% to -$36.2 million in 2025, then fell by 3.09% to -$37.3 million in 2026.
• Per Business Quant, the three latest BCAB Common Equity figures stand at -$37.3 million (Q1 2026), -$36.2 million (Q4 2025), and -$31.2 million (Q3 2025).